The University of Florida Academic Health Center – the most comprehensive academic health center in the Southeast – is dedicated to high-quality programs of education, research, patient care and public service.
The UF College of Dentistry is the only public-funded dental school in Florida and is recognized as one of the top U.S. dental schools for the quality of its educational programs, oral health research enterprise and commitment to patient care and service.
The College of Medicine, the largest of six colleges at the University of Florida Academic Health Center, opened in 1956 with a mission to increase Florida’s supply of highly qualified physicians, provide advanced health-care services to Florida residents and foster discovery in health research.
Founded in 1956, the University of Florida College of Nursing is the premier educational institution for nursing in the state of Florida and is ranked in the top 10 percent of all nursing graduate programs nationwide. The UF College of Nursing continually attracts and retains the highest caliber of nursing students and faculty with a passion for science and caring.
Established in 1923, the College of Pharmacy is the oldest college in the UF Academic Health Center. Ranked among the top schools of pharmacy nationally, the college supports research, service and educational programs enhanced with online technologies.
The College of Public Health & Health Professions (PHHP) is dedicated to providing excellent educational programs that prepare graduates to address the multifaceted health needs of populations, communities and individuals.
The UF College of Veterinary Medicine is Florida’s only veterinary college and provides many unique educational programs for students and services aimed at helping pets, wildlife and endangered species. We offer a a four-year Doctor of Veterinary Medicine programs as well as M.S. and Ph.D. degrees in Veterinary Medical Sciences.
Co-located with the Shands Jacksonville Hospital, the Jacksonville Health Science Center excels in education, research and patient care that expresses our abiding values of compassion, excellence, professionalism and innovation. Our state-of-the-art medical center serves an urban population of 1 million from north Florida to south Georgia.
The UFCOM-J offers accredited graduate medical education residency and fellowship programs, in addition to non-standard fellowship programs. Clinical rotations in all the major disciplines are provided for UFCOM undergraduate medical students and elective rotations to students from other accredited schools.
The UFHSC-J is a clinical teaching site for the Gainesville-based College of Nursing. Students rotate through the various clinical settings on the campus, and primary care centers and specialty care centers located throughout Jacksonville.
The UF College of Pharmacy-Jacksonville offers a four-year Doctor of Pharmacy (Pharm.D.) Program completed entirely in Jacksonville. Also offered on campus is an American Society of Health-System Pharmacists-accredited pharmacy residency program at Shands Jacksonville.
University of Florida Health knows how important ongoing medical learning is to health care providers and the community. That is why we provide online Continuing Medical Education (CME) courses for you to complete for CME credits. These courses share the latest in medical knowledge, teach new patient-relationship skills and help providers deal with relevant current issues.
Learn about UF clinical research studies that are seeking volunteers.
Two people who have been blind since childhood are having their vision restored with a gene therapy developed by University of Florida Health scientists and their collaborators, early-stage clinical trial results and recently published findings show.
Patients who have a form of Leber congenital amaurosis, known as LCA1, are typically blind or have severe visual impairment from birth. The UF Health team and their colleagues have spent decades developing and testing a gene therapy for the inherited genetic disorder. The treatment uses a harmless virus to deliver a functional copy of the gene to the eyes.
To treat LCA1, a gene known as GUCY2D is inserted into the retina. Just days after being treated, both adult patients in the study showed significant increases in their highly light-sensitive photoreceptor cells — essentially restoring their night vision after many decades. The findings were published recently in the journal iScience.
The results in patients culminate 20 years of work by two UF Health scientists: Shannon E. Boye, Ph.D., a professor of cellular and molecular therapy in the UF College of Medicine’s department of pediatrics, and Sanford L. Boye, an associate scientist in the department of pediatrics.
While LCA is considered a rare disease overall, it is the most common cause of inherited blindness in children and affects about 3 in every 100,000 babies.
About one-quarter of LCA cases are caused by mutations in the GUCY2D gene, which interferes with photoreceptor cells’ ability to convert light to neuronal signals. While LCA1 profoundly affects vision, it has one helpful characteristic: The disorder leaves photoreceptor cells, known as rods and cones, largely untouched. Despite these cells being profoundly dysfunctional, their structure remains intact. That gives scientists an opening to improve patients’ vision with a targeted gene therapy.
The patients, a 32-year-old woman and 19-year-old man, had limited daylight vision but were essentially blind at night due to light sensitivity that was 10,000 to 100,000 times below normal before the treatment. Both patients were treated only in one eye in order to best study the gene therapy’s effectiveness.
Eight days after treatment, the patients’ light sensitivity increased substantially, the researchers found. After three months, rod-mediated light sensitivity in the female patient was close to the lower end of normal. The treatments were administered in Philadelphia-area hospitals in conjunction with University of Pennsylvania researchers, who are longtime collaborators on the project.
The published findings come shortly after separate clinical trial results showed the gene therapy delivered clinically meaningful vision improvements and was well-tolerated at its highest dose. The 15 patients, including three children, who received the highest dose had a “significantly larger” change in retinal sensitivity and showed indications of a larger mean change in visual acuity compared with untreated eyes. The data were presented in October at the American Academy of Ophthalmology annual meeting. The clinical trial is being sponsored by Atsena Therapeutics, a Durham, North Carolina gene therapy company. The Boyes are founders and executives of the company.
The trial results show that the gene therapy is well tolerated (no safety concerns) and that treated patients’ exhibit significant improvements in retinal sensitivity and vision, Shannon Boye said. Next, the researchers hope to move the therapy into a key trial before seeking federal regulators’ approval for public use.
“It has been extremely rewarding to watch this program progress from its infancy as my Ph.D. thesis project all the way into a clinical trial that is positively impacting these patients’ lives. This path was paved by the institutional support UF provided me over the years, my amazing gene therapy collaborators and UF’s Office of Technology and Licensing,” she said.
Science Writer, Editor
Doug Bennett joined the UF Health staff in January 2015 as a science writer and editor. His topic areas include anatomy; biochemistry and molecular biology; molecular genetics and microbiology; pathology,…Read More
Together we discover. Together we teach.
Together we care for our patients and our communities.
Together we create unstoppable momentum.